Last reviewed · How we verify
NCT06000306
MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse
trial testing Digital Droplet PCR in Measurable Residual Disease in 192 participants. Completed in 31 July 2023.
31 August 2021
Quick facts
| Lead sponsor | Zhejiang University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 192 |
| Start date | 1 January 2018 |
| Primary completion | 31 August 2021 |
| Estimated completion | 31 July 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Digital Droplet PCR
Conditions studied
- Measurable Residual Disease — all drugs for Measurable Residual Disease →
Sponsor
Zhejiang University
Who can join
Adults 12 to 70, any sex, with Measurable Residual Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A study on the Effectiveness of digital droplet PCR in monitoring measurable residual disease during the early period after allogeneic hematopoietic stem cell transplantation to predict patients at high risk of relapse
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.
Chen W, Huang J, Zhao Y, Huang L, et al · · 2024 · cited 13× · PMID 38689269 · DOI 10.1186/s12967-024-05114-w
Verify or expand the search:
- PubMed search for NCT06000306
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Measurable Residual Disease
Currently open trials in the same condition.
- NCT06595966 — Exploratory Research on Constructing a Computational Biological Model Based on NGS for MRD After Breast Cancer Surgery · recruiting
Other Zhejiang University trials
Trials by the same sponsor.
- NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
- NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
- NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
- NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
- NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06000306 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
- Last refreshed: 22 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06000306.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing